May 21, 2018 / 3:06 PM / 7 months ago

BRIEF-Cosmo Pharmaceuticals' Aemcolo NDA Accepted by FDA

May 21 (Reuters) - Cosmo Pharmaceuticals NV:

* FDA ACCEPTS NEW DRUG APPLICATION FOR AEMCOLO (RIFAMYCIN SV MMX®) AND SETS PDUFA DATE FOR NOVEMBER 16, 2018

* COSMO PHARMACEUTICALS NV - UPON FDA APPROVAL OF AEMCOLO, ARIES PHARMACEUTICALS TO LEAD U.S. COMMERCIAL EFFORTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below